

Status: Currently Official on 15-Feb-2025  
Official Date: Official as of 01-Aug-2023  
Document Type: USP Monographs  
DocId: GUID-146E5387-1F8D-46B8-848C-012A3F986813\_2\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M35930\\_02\\_01](https://doi.org/10.31003/USPNF_M35930_02_01)  
DOI Ref: c1ai1

© 2025 USPC  
Do not distribute

## Griseofulvin Capsules

### DEFINITION

Griseofulvin Capsules contain NLT 90.0% and NMT 115.0% of the labeled amount of griseofulvin ( $C_{17}H_{17}ClO_6$ ).

### IDENTIFICATION

- A. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### • PROCEDURE

**Mobile phase:** Acetonitrile, tetrahydrofuran, and water (35:5:60). Degas for 5 min before use, and stir continuously during use.

**Standard stock solution:** 1.25 mg/mL of [USP Griseofulvin RS](#) in methanol

**Standard solution:** 0.125 mg/mL of [USP Griseofulvin RS](#) in *Mobile phase* from the *Standard stock solution*

**Sample stock solution:** 1.25 mg/mL of griseofulvin prepared as follows. Remove, as completely as possible, the contents of NLT 20

Capsules. Transfer a portion of the powder, equivalent to 125 mg of griseofulvin, to a 100-mL volumetric flask. Add 70 mL of methanol, shake by mechanical means for 30 min, and dilute with methanol to volume. Filter a portion of this solution, discarding the first 5 mL of the filtrate.

**Sample solution:** Nominally 0.125 mg/mL of griseofulvin in *Mobile phase* from the *Sample stock solution*

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 4.6-mm × 25-cm; packing L10

**Flow rate:** 1 mL/min

**Injection volume:** 20  $\mu$ L

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Relative standard deviation:** NMT 2.0%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of griseofulvin ( $C_{17}H_{17}ClO_6$ ) in the portion of Capsules taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P \times F \times 100$$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

$C_S$  = concentration of [USP Griseofulvin RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of griseofulvin in the *Sample solution* (mg/mL)

$P$  = potency of griseofulvin in [USP Griseofulvin RS](#) ( $\mu$ g/mg)

$F$  = conversion factor, 0.001 mg/ $\mu$ g

**Acceptance criteria:** 90.0%–115.0%

**PERFORMANCE TESTS****• DISSOLUTION (711)****Medium:** 5.4 mg/mL of sodium lauryl sulfate in water; 1000 mL**Apparatus 2:** 50 rpm**Time:** 30 min**Diluent:** Methanol and water (40:10)**Sample solution:** Sample per Dissolution (711). Dilute with **Diluent**, if necessary.**Standard solution:** USP Griseofulvin RS at a known concentration similar to that in the **Sample solution**, prepared in the same medium**Instrumental conditions****Mode:** UV**Analytical wavelength:** 291 nm**Analysis****Samples:** *Sample solution and Standard solution*Determine the amount of griseofulvin ( $C_{17}H_{17}ClO_6$ ) dissolved.**Tolerances:** NLT 80% (Q) of the labeled amount of griseofulvin ( $C_{17}H_{17}ClO_6$ ) is dissolved.**Change to read:****• UNIFORMITY OF DOSAGE UNITS (905):** ▲Meet the requirements▲ (CN 1-Aug-2023)**Procedure for content uniformity****Standard solution:** 10 µg/mL of USP Griseofulvin RS in methanol**Sample solution:** Nominally 10 µg/mL of griseofulvin in methanol prepared as follows. Transfer the contents of 1 Capsule to a suitable container; add a volume of methanol sufficient to yield a concentration of griseofulvin NMT 1 mg/mL; shake by mechanical means for 1 h, or longer if necessary, to disperse the specimen completely; and sonicate for 1 min. Centrifuge a portion of this solution, and quantitatively dilute a measured volume of the clear supernatant to obtain a solution containing 10 µg/mL of griseofulvin.**Blank:** Methanol**Instrumental conditions****Mode:** UV**Analytical wavelength:** 292 nm**Analysis****Samples:** *Standard solution, Sample solution, and Blank*Calculate the percentage of the labeled amount of griseofulvin ( $C_{17}H_{17}ClO_6$ ) in the Capsule taken:

$$\text{Result} = (A_U/A_S) \times (C_S/C_U) \times P \times F \times 100$$

 $A_U$  = absorbance of the *Sample solution* $A_S$  = absorbance of the *Standard solution* $C_S$  = concentration of USP Griseofulvin RS in the *Standard solution* (µg/mL) $C_U$  = concentration of the *Sample solution* (µg/mL) $P$  = potency of griseofulvin in USP Griseofulvin RS (µg/mg) $F$  = conversion factor, 0.001 mg/µg

▲ (CN 1-Aug-2023)

**SPECIFIC TESTS****• LOSS ON DRYING (731)****Sample:** 100 mg**Analysis:** Dry at 60° for 3 h in a capillary-stoppered bottle under vacuum at a pressure not exceeding 5 mm of mercury.**Acceptance criteria:** NMT 1.0%**ADDITIONAL REQUIREMENTS****• PACKAGING AND STORAGE:** Preserve in tight containers.**• LABELING:** The label indicates that the griseofulvin contained is known as griseofulvin (microsize).**• USP REFERENCE STANDARDS (11)**USP Griseofulvin RS

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
GRISEOFULVIN CAPSULES	<a href="#">Documentary Standards Support</a>	SM12020 Small Molecules 1

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. Information currently unavailable

**Current DocID: GUID-146E5387-1F8D-46B8-848C-012A3F986813\_2\_en-US**

**DOI: [https://doi.org/10.31003/USPNF\\_M35930\\_02\\_01](https://doi.org/10.31003/USPNF_M35930_02_01)**

**DOI ref: [c1ai1](#)**

OFFICIAL